Crossmark Global Holdings Inc. Lowers Holdings in Agilent Technologies Inc (A)

Crossmark Global Holdings Inc. reduced its holdings in shares of Agilent Technologies Inc (NYSE:A) by 33.3% during the 4th quarter, Holdings Channel reports. The firm owned 26,912 shares of the medical research company’s stock after selling 13,410 shares during the period. Crossmark Global Holdings Inc.’s holdings in Agilent Technologies were worth $1,815,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. We Are One Seven LLC purchased a new position in Agilent Technologies during the 4th quarter worth $33,000. Clean Yield Group purchased a new position in Agilent Technologies during the 4th quarter worth $48,000. Private Capital Group LLC grew its position in Agilent Technologies by 168.8% during the 4th quarter. Private Capital Group LLC now owns 723 shares of the medical research company’s stock worth $49,000 after purchasing an additional 454 shares during the last quarter. Cornerstone Advisors Inc. grew its position in Agilent Technologies by 33.8% during the 4th quarter. Cornerstone Advisors Inc. now owns 811 shares of the medical research company’s stock worth $55,000 after purchasing an additional 205 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. lifted its stake in shares of Agilent Technologies by 65.5% in the 4th quarter. Shine Investment Advisory Services Inc. now owns 907 shares of the medical research company’s stock worth $61,000 after acquiring an additional 359 shares during the period.

A stock opened at $75.33 on Friday. The company has a quick ratio of 2.74, a current ratio of 3.29 and a debt-to-equity ratio of 0.39. Agilent Technologies Inc has a one year low of $60.42 and a one year high of $76.69. The firm has a market capitalization of $24.30 billion, a PE ratio of 27.00, a PEG ratio of 2.13 and a beta of 1.33.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 19th. The medical research company reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Agilent Technologies had a net margin of 6.43% and a return on equity of 19.84%. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.26 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. As a group, research analysts expect that Agilent Technologies Inc will post 3.04 EPS for the current year.

Agilent Technologies announced that its Board of Directors has approved a stock buyback plan on Monday, November 19th that authorizes the company to repurchase $1.75 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 8.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 23rd. Investors of record on Monday, December 31st were paid a $0.164 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.15. The ex-dividend date was Friday, December 28th. This represents a $0.66 annualized dividend and a dividend yield of 0.87%. Agilent Technologies’s dividend payout ratio (DPR) is 23.66%.

In related news, VP Rodney Gonsalves sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $71.06, for a total value of $106,590.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael R. Mcmullen sold 15,923 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $73.20, for a total transaction of $1,165,563.60. Following the completion of the sale, the chief executive officer now owns 492,546 shares of the company’s stock, valued at approximately $36,054,367.20. The disclosure for this sale can be found here. Insiders sold 43,816 shares of company stock valued at $3,242,727 in the last quarter.

A has been the subject of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Agilent Technologies in a research note on Wednesday, January 2nd. They issued a “buy” rating and a $77.00 target price for the company. Alembic Global Advisors cut shares of Agilent Technologies to a “hold” rating in a research note on Monday, December 31st. Morgan Stanley raised their target price on shares of Agilent Technologies from $86.00 to $89.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 20th. ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, Cleveland Research cut shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a research note on Monday, November 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $81.17.

WARNING: “Crossmark Global Holdings Inc. Lowers Holdings in Agilent Technologies Inc (A)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2019/02/08/crossmark-global-holdings-inc-lowers-holdings-in-agilent-technologies-inc-a.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Article: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply